Arando Biotech

arando-biotech.com

Arando is a biotechnology company that researches and markets biopharmaceuticals and cosmeceuticals, providing cutting edge technology and products to address unmet needs. Arando developed an innovative and unique Dermatological range of topical application products, using biopharmaceutical technology and is currently partnering worldwide with pharmaceutical and healthcare companies with marketing and field promotion capabilities, both in own and private label.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

FEN INDUSTRIES EARNS USDA CERTIFIED BIOBASED PRODUCT LABEL FOR TERREPLENISH® SOIL MICROBES

FEN Industries | February 22, 2022

news image

FEN announced today that it has earned the U.S. Department of Agriculture (USDA) Certified Biobased Product label. The product, Terreplenish®, has 97% biobased content. Third-party verification for a product's biobased content is administered through the USDA BioPreferred Program, an initiative created by the Farm Bill. The primary goal of the BioPreferred Program is to increase the development, purchase, and use of biobased products. Biobased products have ...

Read More

Cell and Gene Therapy

ILLUMINA UNVEILS REVOLUTIONARY NOVASEQ X SERIES TO RAPIDLY ACCELERATE GENOMIC DISCOVERIES AND IMPROVE HUMAN HEALTH

Illumina, Inc | September 30, 2022

news image

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery...

Read More

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

news image

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More

AMAGMA THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH INNOVENT BIOLOGICS IN INFLAMMATORY DISEASES

Amagma Therapeutics | January 19, 2022

news image

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

Read More
news image

Industrial Impact

FEN INDUSTRIES EARNS USDA CERTIFIED BIOBASED PRODUCT LABEL FOR TERREPLENISH® SOIL MICROBES

FEN Industries | February 22, 2022

FEN announced today that it has earned the U.S. Department of Agriculture (USDA) Certified Biobased Product label. The product, Terreplenish®, has 97% biobased content. Third-party verification for a product's biobased content is administered through the USDA BioPreferred Program, an initiative created by the Farm Bill. The primary goal of the BioPreferred Program is to increase the development, purchase, and use of biobased products. Biobased products have ...

Read More
news image

Cell and Gene Therapy

ILLUMINA UNVEILS REVOLUTIONARY NOVASEQ X SERIES TO RAPIDLY ACCELERATE GENOMIC DISCOVERIES AND IMPROVE HUMAN HEALTH

Illumina, Inc | September 30, 2022

Illumina, Inc. a global leader in DNA sequencing and array-based technologies, announced the launch of the NovaSeq™ X Series new production-scale sequencers that will push the limits of what is possible with genomic medicine, enabling faster, more powerful, and more sustainable sequencing. Using revolutionary new technology, NovaSeq X Plus can generate more than 20,000 whole genomes per year – 2.5 times the throughput of prior sequencers – greatly accelerating genomic discovery...

Read More
news image

SAMSUNG BIOLOGICS, VIR BIOTECHNOLOGY TEAM UP TO FIGHT COVID-19

BioSpectrum Asia | April 13, 2020

South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...

Read More
news image

AMAGMA THERAPEUTICS ANNOUNCES STRATEGIC PARTNERSHIP WITH INNOVENT BIOLOGICS IN INFLAMMATORY DISEASES

Amagma Therapeutics | January 19, 2022

Amagma Therapeutics, a biotechnology company developing antibody therapeutics for inflammatory diseases, announced a license option agreement with Innovent Biologics, Inc. for up to three enzyme specific inhibitors derived from Amagma’s proprietary SEIZMIC™ Platform. Amagma’s SEIZMIC™ Platform leverages a structure-based approach to identify highly selective antibodies which inhibit dysregulated proteases and other enzymes of interest. The co...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us